These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 7804823)
21. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites. Johannessen JN; Sobotka TJ; Weise VK; Markey SP J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Teismann P; Ferger B Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504 [TBL] [Abstract][Full Text] [Related]
24. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures. Schmidt DE; Ebert MH; Lynn JC; Whetsell WO J Neural Transm (Vienna); 1997; 104(8-9):875-85. PubMed ID: 9451719 [TBL] [Abstract][Full Text] [Related]
25. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Chadi G; Møller A; Rosén L; Janson AM; Agnati LA; Goldstein M; Ogren SO; Pettersson RF; Fuxe K Exp Brain Res; 1993; 97(1):145-58. PubMed ID: 7907549 [TBL] [Abstract][Full Text] [Related]
26. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Choi DY; Lee MK; Hong JT Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220 [TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
28. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. Giovanni A; Sonsalla PK; Heikkila RE J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148 [TBL] [Abstract][Full Text] [Related]
29. Neuroprotective effect of riluzole in MPTP-treated mice. Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056 [TBL] [Abstract][Full Text] [Related]
30. Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice. Oshikawa T; Kuroiwa H; Yano R; Yokoyama H; Kadoguchi N; Kato H; Araki T Cell Mol Neurobiol; 2009 Jul; 29(5):769-77. PubMed ID: 19370411 [TBL] [Abstract][Full Text] [Related]
31. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline. Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878 [TBL] [Abstract][Full Text] [Related]
32. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Nishi K Brain Res; 1997 Oct; 771(1):133-41. PubMed ID: 9383016 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Mori S; Fujitake J; Kuno S; Sano Y Neurosci Lett; 1988 Jul; 90(1-2):57-62. PubMed ID: 2901058 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP Yao L; Dai X; Sun Y; Wang Y; Yang Q; Chen X; Liu Y; Zhang L; Xie W; Liu J J Neurosci Res; 2018 Oct; 96(10):1663-1676. PubMed ID: 30004136 [TBL] [Abstract][Full Text] [Related]
35. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368 [TBL] [Abstract][Full Text] [Related]
36. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820 [TBL] [Abstract][Full Text] [Related]
37. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. Sagi Y; Weinstock M; Youdim MB J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570 [TBL] [Abstract][Full Text] [Related]
38. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Irwin I; Finnegan KT; Delanney LE; Di Monte D; Langston JW Brain Res; 1992 Feb; 572(1-2):224-31. PubMed ID: 1611516 [TBL] [Abstract][Full Text] [Related]
39. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Ferger B; Teismann P; Earl CD; Kuschinsky K; Oertel WH Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):256-61. PubMed ID: 10543426 [TBL] [Abstract][Full Text] [Related]
40. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Heikkila RE; Hess A; Duvoisin RC Life Sci; 1985 Jan; 36(3):231-6. PubMed ID: 3917525 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]